Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Acupuncture and Tuina School, Clinical Research Center for Acupuncture and Moxibustion in Sichuan Province, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
BMC Complement Med Ther. 2024 Aug 14;24(1):306. doi: 10.1186/s12906-024-04608-w.
ST-elevation myocardial infarction (STEMI) is a common acute ischemia heart disease that causes serious damage to human health worldwide. Even though morbidity and mortality have significantly decreased by percutaneous coronary intervention (PCI), an additional cardiac protection strategy is still required. Acupuncture therapy has presented a dominant cardiac protection in many studies lately. Thus, we aim to evaluate the effect and safety of acupuncture as an adjunctive therapy in STEMI patients after PCI through a randomized controlled trial.
METHODS/DESIGN: This study describes a protocol of multicenter, double-blinded, parallel-controlled, randomized controlled trial. Ninety-six patients with STEMI aged 18-85 years who undergoing PCI will be recruited from the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, The Affiliated Third Hospital of Chengdu Traditional Chinese Medicine University/Chengdu Pidu District Hospital of Traditional Chinese Medicine, and Zhaotong Municipal Hospital of Traditional Chinese Medicine. Participants will be randomly assigned (1:1 ratio) to the verum acupuncture plus basic therapy (i.e., treatment) group or the sham acupuncture plus basic therapy (i.e., control) group. These participants will be treated for 5 days and then will be followed up for 24 weeks. Any adverse events will be recorded throughout the study to evaluate safety.
The present study aims to investigate the effect and safety of acupuncture for patients with STEMI after PCI and set up standardized treatment programs for acupuncture of these patients.
This study was registered in the Chinese Clinical Trial Registry (Registration ID: [ChiCTR2400081117]), on February 22, 2024.
ST 段抬高型心肌梗死(STEMI)是一种常见的急性缺血性心脏病,在全球范围内对人类健康造成严重危害。尽管经皮冠状动脉介入治疗(PCI)显著降低了发病率和死亡率,但仍需要额外的心脏保护策略。最近的许多研究表明,针刺疗法具有显著的心脏保护作用。因此,我们旨在通过一项随机对照试验评估针刺作为 PCI 后 STEMI 患者辅助治疗的效果和安全性。
方法/设计:本研究描述了一项多中心、双盲、平行对照、随机对照试验的方案。将从成都中医药大学附属医院、成都中医药大学第三附属医院/成都市郫都区中医医院和昭通市中医医院招募 96 名年龄在 18-85 岁之间接受 PCI 的 STEMI 患者。参与者将按照 1:1 的比例随机分配到真针刺加基础治疗(即治疗)组或假针刺加基础治疗(即对照)组。这些参与者将接受 5 天的治疗,然后进行 24 周的随访。在整个研究过程中记录任何不良事件,以评估安全性。
本研究旨在探讨针刺对 PCI 后 STEMI 患者的疗效和安全性,并为这些患者的针刺治疗制定标准化治疗方案。
本研究于 2024 年 2 月 22 日在中国临床试验注册中心(注册号:[ChiCTR2400081117])注册。